Roquefort Therapeutics Statistics

Total Valuation

Roquefort Therapeutics has a market cap or net worth of GBP 5.55 million. The enterprise value is 5.57 million.

Market Cap	5.55M
Enterprise Value	5.57M

Important Dates

The next estimated earnings date is Friday, December 27, 2024.

Earnings Date	Dec 27, 2024
Ex-Dividend Date	n/a

Share Statistics

Roquefort Therapeutics has 129.15 million shares outstanding. The number of shares has decreased by -8.92% in one year.

Current Share Class	n/a
Shares Outstanding	129.15M
Shares Change (YoY)	-8.92%
Shares Change (QoQ)	-5.35%
Owned by Insiders (%)	41.96%
Owned by Institutions (%)	23.11%
Float	63.53M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	1.13
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-3.61
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 0.79, with a Debt / Equity ratio of 0.12.

Current Ratio	0.79
Quick Ratio	0.79
Debt / Equity	0.12
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-122.19

Financial Efficiency

Return on equity (ROE) is -27.05% and return on invested capital (ROIC) is -17.43%.

Return on Equity (ROE)	-27.05%
Return on Assets (ROA)	-15.86%
Return on Capital (ROIC)	-17.43%
Revenue Per Employee	n/a
Profits Per Employee	-154,168
Employee Count	10
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -39.23% in the last 52 weeks. The beta is 0.05, so Roquefort Therapeutics's price volatility has been lower than the market average.

Beta (5Y)	0.05
52-Week Price Change	-39.23%
50-Day Moving Average	4.05
200-Day Moving Average	4.91
Relative Strength Index (RSI)	45.05
Average Volume (20 Days)	2,340,268

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	-16,000
Operating Income	-1.67M
Pretax Income	-1.70M
Net Income	-1.54M
EBITDA	-1.67M
EBIT	-1.67M
Earnings Per Share (EPS)	-0.01

Full Income Statement

Balance Sheet

The company has 595,662 in cash and 609,697 in debt, giving a net cash position of -14,035 or -0.00 per share.

Cash & Cash Equivalents	595,662
Total Debt	609,697
Net Cash	-14,035
Net Cash Per Share	-0.00
Equity (Book Value)	4.93M
Book Value Per Share	0.04
Working Capital	-179,732

Full Balance Sheet

Cash Flow

Operating Cash Flow	-1.37M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Roquefort Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	8.92%
Shareholder Yield	8.92%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Roquefort Therapeutics has an Altman Z-Score of 2.38. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.38
Piotroski F-Score	n/a